SavedAdd your journal

Journals / Journal of Clinical and Analytical Medicine / 2012 / Cilt: 3 - Sayı: 1

Teofilinin ilaç, diyet, bazı ksenobiyotik ve alışkanlıklarla etkileşmesi ve toksikolojik sonuçları

Interactions of theophylline with drug, diet, some xenobiotics, and habits and their toxicological outcomes

Aylin GÜRBAY
Gönül ŞAHİN
Muhammed CHAREHSAZ
M. Evvah KARAKILIÇ
Pages
117–122
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Therefore, in the present review, some important examples resulted from interactions of theophylline with drug, diet, xenobi-otic, herbal product, habits and their toxicological outcomes have been given.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In vitro and in vivo interactions which are commonly met during drug therapy and their toxicological outcomes are important.
📊
Key Findings & Data:In order to increase effect of certain drugs, interactions, which are called as beneficial interactions, are intentionally applied.
💡
Conclusion & Impact:Therefore, in the present review, some important examples resulted from interactions of theophylline with drug, diet, xenobi-otic, herbal product, habits and their toxicological outcomes have been given.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

In vitro and in vivo interactions which are commonly met during drug therapy and their toxicological outcomes are important. In order to increase effect of certain drugs, interactions, which are called as beneficial interactions, are intentionally applied. However, examples of these interactions are in limited number. On the other hand, untoward and hazardous interactions that cause very important outcomes in toxicological point of view are common. These types of interactions develop more easily during therapy with drugs have a narrow therapeutic window. Theophylline which is used in the treatment of asthma and chronic obstructive pulmonary disease (COPD) has also a narrow therapeutic window. Therefore, in the present review, some important examples resulted from interactions of theophylline with drug, diet, xenobi-otic, herbal product, habits and their toxicological outcomes have been given.

Özet

İlaç tedavisinde sıklıkla karşılaşılan in vitro ve in vivo etkileşmeler ile toksi-kolojik sonuçları güvenli tedavi için önemlidir. Bazı ilaçların etkisini arttırmak için yararlı etkileşme olarak tanımlananlar bilerek uygulanır. Ancak bu etkileşmelerin örnekleri sınırlı sayıdadır. Diğer taraftan toksikolojik açıdan önemli sonuçlara neden olan istenmeyen ve zararlı etkileşmeler yaygındır. Terapötik penceresi dar olan ilaçlarla tedavi sırasında bu tip etkileşmeler daha kolay gelişir. Astım ve kronik obstruktif akciğer hastalığı (KOAH) tedavisinde kullanılan teofilinin de terapötik penceresi dardır. Bu nedenle sunulan bu derlemede teofilinin ilaç, diyet, ksenobiyotik, bitkisel ürün ve alışkanlıklarla etkileşmelerinden kaynaklanan bazı önemli örnekler ve toksikolojik sonuçları verilmiştir.

🔖

Cite This Article

GÜRBAY, A., ŞAHİN, G., CHAREHSAZ, M., KARAKILIÇ, M. E. (2022). Teofilinin ilaç, diyet, bazı ksenobiyotik ve alışkanlıklarla etkileşmesi ve toksikolojik sonuçları. Journal of Clinical and Analytical Medicine, Cilt: 3 - Sayı: 1, 117–122. https://ajindex.com/articles/561412

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Bellibaş SE, editor. Rasyonel İlaç Rehberi. İzmir: Egem Tıbbi Yayıncılık; 1994
  2. Kayaalp SO, editor. Rasyonel Tedavi Yönünden Tıbbi Farmakoloji. Ankara: Hacettepe Taş Kitapçılık; 2005
  3. Lu FC, Kacew S, editors. Lu's Basic Toxicology, Fundamentals, Target Organs and Risk Assessment. London: Taylor & Francis; 2002
  4. Şahin G, Girgin G. İlaç-Besin, İlaç-Alkol ve İlaç-Bitkisel Kökenli Ürün Etkileşmeleri. Mised 2003; 5-6: 92-109
  5. Clark WG, Brater DC, Johnson AR, editors. Goth's Medical Pharmacology. Washington D.C: Mosby; 2002
  6. Abernethy DR, Arnold GJ, Azarnoff D, editors. Mosby's Drug Consult. St. Louis: Mosby Inc, 2002
  7. Jonkman JH, Nicholson KG, Farrow PR, Eckert M, Grasmeijer G, Oosterhuis B, et al. Effects of alpha-interferon on theophylline pharmacokinetics and metabolism. Br J Clin Pharmacol 1989; 27(6): 795-802
  8. Atkinson AJ, Abernethy DR, Daniels CE, Dedrick RL, Markey SP, editors. Principles of Clinical Pharmacology. London: Elsevier; 2007
  9. Kobayashi K, Nakajima M, Chiba K, Yamamoto T, Tani M, Ishizaki T, et al. Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalysed by human CYP1A2. Br J Clin Pharmacol 1998; 45(4): 361-368
  10. Fuhr U, Anders EM, Mahr G, Sorgel F, Staib AH. Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro. An-timicrob Agents Chemother 1992; 36(5): 942-948
  11. Bertram G. Katzung editor. Basic & Clinical Pharmacology. McGraw-Hill; 2003
  12. Segev S, Rehavi M, Rubinstein E. Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor. Antimicrob Agents Chemother 1 988; 32(11): 1624-1626
  13. Spivey JM, Laughlin PH, Goss TF, Nix DE. Theophylline toxicity secondary to ciprofloxacin administration. Ann Emerg Med 1991; 20(10): 1131 -1134
  14. Yao C, Kunze KL, Kharasch ED, Wang Y, Trager WF, Ragueneau I, et al. Fluvox-amine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2. Clin Pharmacol Ther 2001; 70(5): 415-424
  15. Colli A, Buccino G, Cocciolo M, Parravicini R, Elli GM, Scaltrini G. Ticlopidine-theophylline interaction. Clin Pharmacol Ther 1987; 41(3): 358-362
  16. Koch KM, Ricci BM, Hedayetullah NS, Jewell D, Kersey KE. Effect of alosetron on theophylline pharmacokinetics. Br J Clin Pharmacol 2001; 52(5): 596-600
  17. Ahn HC, Lee YC. The clearance of theophylline is increased during the initial period of tuberculosis treatment. Int J Tub er